IL37 and psoriasis: Further studies found that, compared with control group, improved local epidermal hyperplasia and ulceration, reduced epithelial hyperplasia, vasodilatation and inflammatory cell infiltration, and reduced symptom score of psoriasis were observed in K14-VEGF transgenic mice (K14-VEGF-Tg mice) injected with IL-37 plasmid [68].